Accustem Sciences, Inc. ACUT

Annual Quarterly

No annual revenue total was found in ACCUSTEM SCIENCES, INC.'s SEC filings.

Accustem Sciences, Inc. (ACUT) files with the SEC under industry code 2834, Pharmaceutical Preparations.

Revenue
—
Net income (TTM)
$-1.65M
-7.2% vs year-ago TTM
Operating cash flow (TTM)
$-1.20M
-147.8% vs year-ago TTM
Free cash flow
$-1.82M
EPS (TTM)
$-0.10
+13.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
16.07M
+32.8% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ACUT (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1850767
Former names
AccuStem Sciences Ltd (until Jul 1, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating income
-$1.8M
-$1.5M
-$2.1M
-$3.7M
Net income
-$1.8M
-$1.5M
-$2.1M
-$3.7M
Diluted EPS
-$0.12
-$0.13
-$0.18
—
Operating cash flow
-$850,389
-$664,066
-$1.6M
-$1.8M
Free cash flow
—
—
—
-$1.8M
Total assets
$1.5M
$50,851
$133,897
$939,689
Total liabilities
$5.0M
$3.4M
$2.2M
$1.1M
Stockholders' equity
-$3.4M
-$3.3M
-$2.1M
-$139,550
Cash and investments
$13,929
$5,046
$21,481
$733,978

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
10-K Annual report Apr 14, 2026 Dec 31, 2025
8-K Current report
Other events
 Nov 26, 2025 Nov 26, 2025
10-Q Quarterly report Nov 12, 2025 Sep 30, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025

All 76 Accustem Sciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.